Life sciences innovators in Europe are no longer entitled to patent term extension rights for new indications of drugs previously approved for other uses, following last week\u2019s Santen judgment in which the CJEU in effect overturned its own 2012 decision in Neurim.<\/p>\n\n\n\n
[\u2026]<\/p>\n\n\n\n
\u201cI think the Regulation needs a completely new start,\u201d comments Maiwald\u2019s Dirk Buehler<\/a>. \u201cIn general, the Regulation as it is today has moved a pretty long way from the original motives for putting it in its place \u2013 to foster innovation. A common theme is that certain types of research are discriminated against, such as research into second medical indications and [because of other decisions relating to Article 3(a)] innovative discoveries relating to principle of very broad application. The explanatory memorandum originally said that all types of research should be fostered and should receive SPC protection.\u201d<\/p>\n\n\n\n [\u2026]<\/p>\n\n\n\n